Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTX
Healthcare|Biotechnology|USA
$434.30
-4.41 (-1.01%)
DCF (FCF)
$183.42
Tangible Book
$67.54
Graham Number
$167.26
Earnings Power
$127.09

Upcoming Data Readouts (21)

Sep 2026
Est. completion
P3Type 1 Diabetes
An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant
NCT06832410n=10
Oct 2026
Est. completion
P3Cystic Fibrosis
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
NCT05444257n=822
Nov 2026
Est. completion
P1Cystic Fibrosis
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants
NCT07283770n=128
Dec 2026
Est. completion
P1P2Myotonic Dystrophy Type 1 (DM1)
A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
NCT06185764n=44
Dec 2026
Est. completion
P1P2Cystic Fibrosis
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
NCT05668741n=39
Dec 2026
Est. completion
P2Proteinuric Kidney Disease
Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities
NCT06794996n=45
Dec 2026
Est. completion
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease
NCT06747572n=401
Jan 2027
Est. completion
P3Diabetic Peripheral Neuropathic Pain
Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)
NCT06696443n=455
Feb 2027
Est. completion
P1Pain
Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants
NCT07378865n=12
Mar 2027
Est. completion
P1Cystic Fibrosis
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants
NCT07437105n=128
Apr 2027
Est. completion
P3Diabetic Peripheral Neuropathic Pain
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
NCT07231419n=734
Apr 2027
Est. completion
P3Cystic Fibrosis
Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del
NCT05331183n=297
May 2027
Est. completion
P3Diabetic Peripheral Neuropathic Pain
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
NCT06628908n=1,100
Jun 2027
Est. completion
P3Beta-Thalassemia
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
NCT05477563n=26
Jun 2027
Est. completion
P3Diabetes Mellitus, Type 1
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
NCT04786262n=52
Jul 2027
Est. completion
P2Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
NCT07161037n=24
Sep 2027
Est. completion
P3Cystic Fibrosis
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older
NCT06460506n=50
Jan 2028
Est. completion
P3Immunoglobulin A Nephropathy
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06564142n=605
Jun 2028
Est. completion
P2P3Proteinuric Kidney Disease
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
NCT05312879n=466
Dec 2028
Est. completion
P2P3Primary Membranous Nephropathy
A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
NCT07204275n=176

Awaiting Results (3)

Trials past primary completion date but still active — data readout may be imminent.

May 2026
P3
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
NCT05329649
May 2026
P3
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
NCT05356195
May 2026
P1P2
A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
NCT05791201

Recent Press Releases